Novo, a life sciences company, led a $100m Series A round in Ray Therapeutics, an optogenetics company, with participation from Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund, and 4BIO Capital. “This Series A financing marks a significant milestone in our mission to address the urgent unmet medical need of patients with blinding diseases. We are incredibly grateful for the support of 4BIO Capital, our other early investors and the California Institute for Regenerative Medicine who have been instrumental in our growth. We are excited by this new funding, led by Novo Holdings, with a top-tier investor syndicate which will accelerate our pipeline of potential first-in-class optogenetic gene therapies for patients," Paul Bresge, Ray Therapeutics CEO & Co-Founder.